Association of interleukin-17A gene polymorphisms and susceptibility to systemic lupus erythematosus in Egyptian children and adolescents: a multi-centre study
Restricted accessResearch articleFirst published online June, 2020
Association of interleukin-17A gene polymorphisms and susceptibility to systemic lupus erythematosus in Egyptian children and adolescents: a multi-centre study
Recently, the interleukin-17A (IL-17A) gene has emerged as a potential candidate gene for autoimmune disorders, including systemic lupus erythematosus (SLE).
Objectives
This study aimed to investigate whether IL-17A polymorphisms at rs2275913 G/A, rs8193036 C/T and rs3748067 C/T could be susceptibility markers for juvenile-onset SLE (JSLE) and lupus nephritis (LN) in Egyptian children and adolescents.
Methods
In this multi-centre study, we genotyped 320 patients diagnosed with JSLE and 320 matched control children for three IL-17A polymorphisms at rs2275913 G/A, rs8193036 C/T and rs3748067 C/T using TaqMan probe-based real-time polymerase chain reaction. Meanwhile, IL-17A serum levels were assessed using ELISA.
Results
The IL-17 rs2275913 A/A genotype and A allele were more represented in JSLE patients compared to the control group (21% vs. 7%, odds ratio (OR) = 3.8, 95% confidence interval (CI) 1.78–5.5, p = 0.001, pBonf = 0.003 for the A/A genotype; 37% vs. 29%, OR = 1.4, 95% CI 1.11–1.8, p = 0.003, pBonf = 0.009 for the A allele. No significant difference was found for IL-17 rs8193036 and rs3748067 single nucleotide polymorphisms (SNPs) in genotype distribution or allele frequencies (p>0.05). Patients carrying the IL-17 rs2275913 A/A genotype and A allele were more likely to develop LN (OR = 5.64, 95% CI 2.39–13.77, pBonf = 0.001 for the A/A genotype; OR = 2.73, 95% CI 1.84–4.07, pBonf = 0.02 for the A allele).
Conclusion
The IL-17 rs2275913 A allele and A/A genotype were associated with high IL-17 serum levels and may contribute to susceptibility to JSLE and the development of LN in Egyptian children and adolescents. However, no significant association was evident between the studied IL-17A SNPs and other clinical phenotypes, disease activity scores or laboratory profile of JSLE.
SilvaCAAvcinTBrunnerHI.Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken)2012;
64: 1787–1793.
2.
Bader-MeunierBArmengaudJBHaddadE, et al.
Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr2005;
146: 648–653.
3.
MorganTAWatsonLMcCannLJBeresfordMW.Children and adolescents with SLE: not just little adults. Lupus2013;
22: 1309–1319.
4.
SatoVAMarquesIDGoldensteinPT, et al.
Lupus nephritis is more severe in children and adolescents than in older adults. Lupus2012;
21: 978–983.
5.
ZhangZKyttarisVCTsokosGC.The role of IL-23/IL-17 axis in lupus nephritis. J Immunol2009;
183: 3160–3169.
6.
Pacheco-LugoLSáenz-GarcíaJNavarro QuirozE, et al.
Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. Lupus2019;
28: 34–43.
7.
TalaatRMAlrefaeySABassyouniIHAshourMERaoufAA.Genetic polymorphisms of interleukin 6 and interleukin 10 in Egyptian patients with systemic lupus eythematosus. Lupus2016;
25: 255–264.
8.
ApostolidisSACrispínJCTsokosGC.IL-17-producing T cells in lupus nephritis. Lupus2011;
20: 120–124.
9.
WoltmanAMDe HaijSBoonstraJGGobinSJDahaMRVan KootenC.Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol2000;
11: 2044–2055.
10.
WrightJFBennettFLiB, et al.
The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol2008;
181: 2799–2805.
11.
FouserLAWrightJFDunussi-JoannopoulosKCollinsM.Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev2008;
226: 87–102.
12.
WongCKLitLCTamLSLiEKWongPTLamCW.Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity.Clin Immunol2008;
127: 385–393.
13.
ZhaoXFPanHFYuanH, et al.
Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep2010;
37: 81–85.
14.
KwanBCTamLSLaiKB, et al.
The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxford)2009;
48: 1491–1497.
15.
TenbrockKJuangYTTolnayMTsokosGC.The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism.J Immunol2003;
170: 2971–2976.
16.
ReynoldsJMAngkasekwinaiPDongC.IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev2010;
21: 413–423.
17.
TangHPeiHXiaQ, et al.
Role of gene polymorphisms/haplotypes and serum levels of interleukin-17A in susceptibility to viral myocarditis. Exp Mol Pathol2018;
104: 140–145.
18.
EspinozaJLTakamiANakataK, et al.
A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One2011;
6: e26229.
19.
PetriMOrbaiAMAlarcónGS, et al.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012;
64: 2677–2686.
20.
YeeCSFarewellVTIsenbergDA, et al.
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.Rheumatology (Oxford)2011;
50: 982–988.
21.
WeeningJJD’AgatiVDSchwartzMM, et al.
The classification of glomerulonephritis in systemic lupus erythematosus revisited.J Am Soc Nephrol2004;
15: 241–250. Erratum in: J Am Soc Nephrol 2004; 15: 835–836.
22.
PengYZhouBWangYY, et al.
Analysis of IL-17 gene polymorphisms in Chinese patients with dilated cardiomyopathy. Hum Immunol2013;
74: 635–639.
23.
NordangGBVikenMKHollis-MoffattJE, et al.
Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatology (Oxford)2009;
48: 367–370.
24.
YanNYuYLYangJ, et al.
Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases.Autoimmunity2012;
45: 533.
25.
ArisawaTTaharaTShibataT, et al.
The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol2008;
28: 44–49.
26.
PashaHFTantawyEAYoussefMA.Osteopontin and interleukin-17A genes polymorphisms in Egyptian systemic lupus erythematosus patients: a relation to disease activity and severity. Gene2019;
702: 107–113.
27.
SharifzadeMNaeimiSNasiriMArianniaSFarrokhsereshtR.IL-17A gene polymorphism at position G197A and systemic lupus erythematosus. Rheum Res2018;
3: 107–112.
28.
HammadAMosaadYMHammadEM, et al.
Interleukin-17A rs2275913, interleukin-17F rs763780 and rs2397084 gene polymorphisms as possible risk factors in juvenile lupus and lupus related nephritis. Autoimmunity2016;
49: 31–40.
29.
RanaAMinzRWAggarwalRAnandSPasrichaNSinghS.Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus2012;
21: 1105–1112.
30.
De Peliçari KdeOPostalMSinicatoNA, et al.
Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo)2015;
70: 313–317.
31.
YaziciMUOrhanDKaleGBesbasNOzenS.Studying IFN-gamma, IL-17 and FOXP3 in pediatric lupus nephritis. Pediatr Nephrol2014;
29: 853–862.
32.
DedongHFeiyanZJieSXiaoweiLShaoyangW.Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients. Immunol Lett2019;
210: 33–39.
33.
MizuiMKogaTLiebermanLA, et al.
L-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunol2014;
193: 2168–2177.
34.
WangYItoSChinoY, et al.
Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol2010;
159: 1–10.
35.
DongGYeRShiW, et al.
IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl)2003;
116: 543–548.
36.
LiuXKLinXGaffenSL.Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J Biol Chem2004;
279: 52762–52771.
37.
CrispínJCTsokosGC.IL-17 in systemic lupus erythematosus. J Biomed Biotechnol2010;
2010: 943254.
38.
NalbandianACrispínJCTsokosGC.Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol2009;
157: 209–215.
39.
WeaverCTHattonRD.Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol2009;
9: 883–889.
40.
RöhnTAJenningsGTHernandezM, et al.
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol2006;
36: 2857–2867.
41.
LubbertsE.IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?Cytokine2008;
41: 84–91.
